Phase 2b Study of GSK4532990 in Adults With NASH

This is a placebo-controlled Phase 2 study in biopsy-confirmed advanced disease, which is a credible design, but the efficacy bar is high. The listed primary outcomes are histologic endpoints at Week 52 in the F3 cohort: fibrosis improvement without worsening of NASH and NASH resolution without worsening of fibrosis. Those are clinically meaningful but difficult endpoints in NASH, especially in advanced fibrosis, where reversal is harder and placebo-adjusted effects can be modest. Requiring central biopsy-based histology also introduces read variability and missing-data risk, which can dilute signal. The study includes F3/F4 patients overall, adding operational complexity, even though the primaries focus on F3. Positives are the large experienced sponsor and a standard placebo comparator, which should reduce execution noise. However, from the trial fields alone there is no prior efficacy evidence, biomarker enrichment, or mechanistic validation to justify an above-base success rate. With a challenging indication, stringent histologic definitions, and Phase 2 uncertainty, the intrinsic chance of a clearly positive readout looks below even odds.

GSK4532990 targets HSD17B13 via RNAi, a genetically validated target where loss-of-function mutations confer 30-50% protection against chronic liver disease. Phase 1 data showed robust target knockdown (84% mRNA reduction), ALT reductions up to 44%, and modest liver fat/stiffness improvements in some patients. However, translating genetic protection into therapeutic benefit in established F3 fibrosis is uncertain—the mechanism is primarily anti-inflammatory rather than directly antifibrotic. The primary endpoint (≥1 stage fibrosis improvement with no NASH worsening at Week 52) is a high bar historically. NASH Phase 2b trials have a poor track record overall (~30-35% success on histological endpoints). While efruxifermin (FGF21) and resmetirom (THR-beta) succeeded, these target metabolic pathways more directly. HSD17B13 inhibition has never been proven on histological endpoints. The trial is past its estimated completion date with no disclosed results, which is not uncommon but does not provide a positive signal. GSK's continued pipeline investment is mildly encouraging but not decisive. Balancing genetic validation against mechanistic uncertainty and the challenging endpoint yields a below-coin-flip estimate.

This Phase 2b trial of GSK4532990 targets NASH with advanced fibrosis (F3/F4). The dual primary endpoints are clinically meaningful: fibrosis improvement (≥1 stage) without NASH worsening, and NASH resolution without fibrosis worsening at week 52. These are validated histological endpoints used in regulatory decisions. The study is past its primary completion date (61 days overdue), suggesting data may be imminent. GSK's resources and NASH program experience provide operational credibility. However, NASH drug development has historically seen high attrition rates in Phase 2/3 due to complex endpoint assessment and variable placebo responses. The 52-week duration is appropriate for fibrosis endpoints. Given the robust trial design, major pharma sponsor, and pending data, the probability of positive results is moderately favorable at approximately 52%.

This Phase 2b NASH trial by GSK has a solid design focusing on participants with advanced fibrosis (F3/F4), a high-need population. The dual primary endpoints—fibrosis improvement and NASH resolution—are clinically meaningful and align with regulatory precedent. The 52-week treatment duration is standard for histological outcomes. Sponsor GSK has substantial experience in metabolic diseases. However, the NASH therapeutic landscape is notoriously challenging, with many late-stage failures. The binary call is a cautious 'yes' based on reasonable trial design and sponsor capability, but the high historical failure rate in NASH limits confidence.

This Phase 2b double-blind placebo-controlled trial tests GSK4532990 in adults with biopsy-confirmed NASH and advanced fibrosis (F3/F4), reporting co-primary endpoints in F3 cohort at Week 52: (1) ≥1-stage CRN fibrosis improvement without NASH worsening (no NAS increase in steatosis, ballooning, inflammation); (2) NASH resolution (ballooning 0, inflammation 0-1) without fibrosis worsening. Design is strong with randomization and histological gold-standard endpoints required by regulators, but fibrosis scores have inter-reader variability (kappa 0.5-0.7) and placebo rates 10-25% in NASH trials. F3 population is enriched but biopsy procedures dropouts common (15-20%). No prior efficacy data on GSK4532990; NASH Phase 2 fibrosis improvement success <25% historically (e.g., GLP-1s modest, many FXR/ACC inhibitors fail). GSK sponsor excels in execution, yet primary completion overdue 61 days ('Active, Not Recruiting') hints biopsy/analysis delays, mild operational risk. Low disclosure risk pre-topline. Stringent endpoints in failure-prone field cap intrinsic YES at 30%. Binary NO.

This Phase 2b NASH trial (NCT05583344) for GSK4532990 has passed its primary completion date by two months, with results imminent. The primary endpoints—fibrosis improvement without NASH worsening and NASH resolution without fibrosis worsening—are historically difficult endpoints where many candidates have failed. While GSK's ACC inhibitor mechanism has biological plausibility, the F3 cohort faces a high bar for histological improvement in a 52-week treatment window. The 'Active, Not Recruiting' status confirms the trial executed fully, reducing operational risk. However, without disclosed interim signals or a robust efficacy track record for this specific molecule, the inherent probability of success in NASH histology trials remains below 50%. I estimate a 45% probability of positive results, reflecting the substantial mechanistic and clinical uncertainty typical of this indication and endpoint set.

Phase 2b NASH fibrosis trials face inherent challenges. GSK4532990 targets F3/F4 patients with dual primary endpoints: fibrosis improvement without NASH worsening, and NASH resolution without fibrosis worsening. The 52-week treatment duration is standard but tight for histological change. GSK's NASH pipeline has mixed history; this asset is relatively early-stage with limited public mechanistic data. The F3 cohort focus is pragmatic (F4 patients often progress regardless), but placebo response in NASH histology trials typically runs 15-25%. The 'Active Not Recruiting' status with primary completion 61 days past suggests data lock is imminent or complete, reducing operational uncertainty. Positive signals from interim analyses would likely have triggered disclosure, creating some negative inference. However, GSK's continued investment and trial completion without early termination suggests detectable efficacy. The dual endpoint structure requires only one success for typical 'positive' interpretation, improving odds modestly.

The HORIZON Phase 2b trial for GSK4532990 (ARO-HSD) evaluates an RNAi therapeutic targeting HSD17B13 in patients with NASH and advanced (F3) fibrosis. While HSD17B13 loss-of-function mutations are genetically validated to protect against the progression of chronic liver diseases over a lifetime, translating this prophylactic genetic advantage into an acute therapeutic intervention that can actively reverse established F3 fibrosis within just 52 weeks presents a formidable clinical hurdle. Prior Phase 1/2 data demonstrated robust target mRNA knockdown and ALT reductions, but HSD17B13 knockdown did not produce the massive liver fat reductions typically seen with successful metabolic agents (e.g., FGF21s, GLP-1s, THR-beta agonists). Without driving profound metabolic improvements, relying primarily on fibro-protective and anti-inflammatory mechanisms to meet the strict FDA-mandated primary endpoint—≥ 1 stage improvement in histological fibrosis without worsening of NASH—is historically risky. Trials of other non-metabolic liver targets have often failed to reverse advanced fibrosis in 1-year timeframes. Given the stringent biopsy-based endpoints in NASH, the intrinsic probability of success is below a coin flip.

The Phase 2b study of GSK4532990 in adults with NASH has a clear primary endpoint focused on histological fibrosis improvement and NASH resolution. The study is actively recruiting, and the primary completion date is near. Given the unmet medical need in NASH treatment and the specific mechanism of GSK4532990, there's a reasonable expectation of positive results. However, the complexity of NASH pathology and variability in patient response introduce uncertainty.